Tissue Regenix Group PLC (AIM:TRX), a maker of regenerative medical devices, has extended a distribution agreement between its subsidiary, CellRight Technologies, and Arthrex, a specialist in arthroscopy and sports medicine.
The agreement, originally signed in 2017, now runs until October 2029, with options for further renewal.
CellRight specialises in osteobiologics, materials designed to aid the healing of fractures and bone defects, which are used in orthopaedic, spine, and foot and ankle procedures.
This extended partnership ensures surgeons will continue to have access to CellRight’s advanced healing products, along with Arthrex’s surgical tools and techniques, aimed at improving patient outcomes. The deal highlights a long-term commitment to advancing orthopaedic care.
"The extension of our long-term distribution agreement will continue to allow physicians and patients access to CellRight's innovative orthobiologics through the Arthrex network," said Tissue Regnix CEO Daniel Lee.
"Patient outcomes are positively impacted by orthobiologic products together with the advanced technologies and training from Arthrex. This shared vision is at the core of this strategic partnership."